DCT HCWC LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$81,596	82
2024	Research	$391,163	216
2023	Research	$351,293	179
2022	Research	$96,712	51
2021	Research	$972	3
2020	Research	$8,100	4

Breakdown

Who paid Research payments · program years 2020–2025

Sumitomo Pharma America, Inc. $806,619 441 payments
Myovant Sciences GmbH $72,091 44 payments
Sage Therapeutics, Inc. $33,692 14 payments
Chiesi USA, Inc. $17,433 36 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $373,730 180 payments
Serene $317,663 146 payments
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $81,596 82 payments
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $53,192 41 payments
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis $52,529 36 payments
A Study to Evaluate the Efficacy and Safety of Sage-217 in Participants With Severe Postpartum Depression (PPD) $33,692 14 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $17,433 36 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.